Novel Drug Delivery Systems (Ndds) Market
This report on global novel drug delivery systems (NDDS) studies the overall market scenario, the ongoing trends, future commercial prospects, and the competition in the novel drug delivery systems market. For this study, the global novel drug delivery systems market is studied for the route of administration type, carrier type, and geographical distribution. This study estimates the prospects of the NDDS post introduction of certain novel drug delivery systems.
Based on route of administration types, the global novel drug delivery systems market is categorized into oral, injectable, pulmonary, transdermal, and other segments. The market estimates in terms of revenue forecast for each of these segments from their product launch until the year 2022 are provided in this study, along with their respective CAGRs for the corresponding periods through 2022.
Based on carrier types, the global novel drug delivery systems market is categorized into liposomes, nanoparticles, microspheres, monoclonal antibodies, and others (niosomes and resealed erythrocytes as drug carriers). The market estimates in terms of revenue forecast for each of these segments from their product launch until the year 2022 are provided in this study, along with their respective CAGRs for the corresponding periods through 2022.
The novel drug delivery systems market has been geographically categorized into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Each geography market is further split to provide market revenue for select countries such as the U.S., Canada, U.K., Germany, China, and Japan. Market size and forecast for these segments from 2013 to 2022 and their CAGRs for the period 2016 to 2022 are provided in this report.
Apart from the quantitative information, this report includes qualitative information sets such as drivers, challenges and opportunities, market inclination insights, major commercial events, device mechanism of artificial pancreas device systems, and benefits to the stakeholders in this market. This report also includes tools such as attractive investment proposition, Porter’s Five Forces model, and market positioning of key players to assess the overall market competition. This report concludes with profiles of certain market players that have a foothold in the global novel drug delivery systems market.
The major key players profiled in the novel drug delivery systems market are business description, financial health, budget allocation, product portfolio, and news coverage. The major players profiled in this report include 3M Company, Abbott Laboratories Ltd., Amgen Inc., AstraZeneca Plc, Bausch & Lomb, Baxter International Inc., Bayer AG, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Celgene Corporation, Cephalon, Inc., Genentech Inc., Genzyme Corporation, GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co., Novartis AG, Pfizer Inc., Roche Holding AG, Sanofi SA, and Teva Pharmaceutical Industries Ltd.
Type of Carrier Segmentation Analysis
Based on the type of carrier, the novel drug delivery systems (NDDS) market is segmented into:
- Monoclonal antibodies
- Others (Niosomes and Resealed erythrocytes as drug carriers)
In the base year 2015, the liposomes and microspheres collectively attribute the largest share in the market in terms of revenue (USD). According to market experts, liposomes have the distinct advantages of being nontoxic and biodegradable as they are composed of naturally available substances. The key factors assisting the growth of the liposomes market are biologically active materials encapsulated within liposomes that are protected to varying extent from immediate dilution or degradation, which assists drug carrier systems for the transport of drugs and other bioactive capsules to disease-affected organs. In addition, the unique ability of liposomes to entrap drugs both in an aqueous and a lipid phase make such delivery systems attractive for hydrophilic and hydrophobic drugs. On the other hand, microspheres possess several advantages, such as facilitating accurate delivery of small quantities of potent drugs and reducing the concentration of drugs at desired sites and providing protection for unstable drugs before and after administration before their availability at the site of action. Thus, liposomes and microspheres are the largest markets in novel drug delivery systems.
Route of Administration Type Segmentation Analysis
Based on the route of administration type, the novel drug delivery systems market is segmented into:
- Oral Drug Delivery Systems
- Injectable Drug Delivery Systems
- Pulmonary Drug Delivery Systems
- Transdermal Drug Delivery Systems
In the base year 2015, injectable and oral drug delivery systems together accounted for more than half of the overall market share in the novel drug delivery systems market. Oral drug delivery systems possess advantages associated with cost-efficient manufacturing and the safest and most convenient route of administration. However, protein- and peptide-based face difficulty in crossing mucosal surfaces and biological membranes. Through several ongoing research studies, the market for oral drug delivery systems in novel drug delivery systems is expected to grow during the forecast period. Injectable drug delivery systems are the most preferred as they meet many benefits over other dosage forms in many cases, such as unconsciousness, and nausea, in emergency clinical episodes. The injectable administration route is the most common and efficient for delivering active drug substances with poor bio-availability and drugs with a narrow therapeutic index.
For 0this study, the global novel drug delivery systems (NDDS) market is categorized into:
- North America
- Asia Pacific
- Latin America (LATAM)
- Middle East and Africa (MEA)
In 2015, North America accounted for the largest share of the global novel drug delivery systems market, followed by Asia-Pacific, Europe, LATAM, and MEA. The Asia-Pacific region (comprising Japan, China, and India as major countries) is anticipated to grow at the fastest CAGR from 2016 – 2022. The key factors, such as enormous rising demand and acceptance for novel drug delivery systems from people, supportive government policies, and physicians preferring novel drug delivery systems over traditional drug delivery systems in North America and Europe, are expected to drive the market throughout the forecast period 2016 – 2022. The Asia Pacific was anticipated to project significant growth during the forecast period due to increasing government support for novel drug delivery systems, rising awareness related to novel therapies, and developing healthcare infrastructure.